Loading...
As with many solid-tumor malignances, colorectal cancer (CRC) is more common in older patients, who are often underrepresented in clinical trials and for whom application of standard therapies often leads to greater rates of toxicity. Moreover, recent studies have questioned whether older patients would receive the same benefits from contemporary oxaliplatin- and capecitabine-based treatments that younger patients achieve.
To examine this issue, investigators from the Medical Research Council in the U.K. conducted a 2×2 factorial, randomized, phase III trial involving 459 older or frail patients (mean age, 74; WHO performance status, ≤2) with previously untreated, metastatic CRC. Patients were randomized to receive standard intravenous 5-flu…